glibenclamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antihyperglycaemics | 1314 | 10238-21-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An antidiabetic sulfonylurea derivative with actions similar to those of chlorpropamide.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 7 | mg | O |
| 10 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.00 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 0 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.58 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 82 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.08 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.82 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.02 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.20 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 1, 1984 | FDA | SANOFI AVENTIS US |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hypoglycaemia | 632.71 | 12.03 | 351 | 21264 | 53230 | 50530279 |
| Blood glucose increased | 344.34 | 12.03 | 267 | 21348 | 71057 | 50512452 |
| Lactic acidosis | 135.48 | 12.03 | 113 | 21502 | 33242 | 50550267 |
| Blood glucose decreased | 130.99 | 12.03 | 87 | 21528 | 18124 | 50565385 |
| Cardiac failure congestive | 130.15 | 12.03 | 170 | 21445 | 84212 | 50499297 |
| Coronary artery disease | 127.61 | 12.03 | 104 | 21511 | 29622 | 50553887 |
| Myocardial infarction | 118.53 | 12.03 | 167 | 21448 | 88860 | 50494649 |
| Diabetes mellitus inadequate control | 104.82 | 12.03 | 67 | 21548 | 13078 | 50570431 |
| Glycosylated haemoglobin increased | 84.41 | 12.03 | 54 | 21561 | 10552 | 50572957 |
| Off label use | 58.65 | 12.03 | 70 | 21545 | 474356 | 50109153 |
| Hyperglycaemia | 58.64 | 12.03 | 75 | 21540 | 36330 | 50547179 |
| Hypoglycaemic coma | 50.21 | 12.03 | 23 | 21592 | 2310 | 50581199 |
| Hyperkalaemia | 40.17 | 12.03 | 73 | 21542 | 48016 | 50535493 |
| Contraindicated product administered | 39.11 | 12.03 | 8 | 21607 | 148950 | 50434559 |
| Alopecia | 37.31 | 12.03 | 30 | 21585 | 245017 | 50338492 |
| Pancreatitis | 34.72 | 12.03 | 64 | 21551 | 42550 | 50540959 |
| Glossodynia | 32.96 | 12.03 | 5 | 21610 | 115564 | 50467945 |
| Blood glucose fluctuation | 32.71 | 12.03 | 21 | 21594 | 4125 | 50579384 |
| Drug ineffective | 32.15 | 12.03 | 212 | 21403 | 819121 | 49764388 |
| Torsade de pointes | 30.29 | 12.03 | 31 | 21584 | 11804 | 50571705 |
| Product use in unapproved indication | 28.82 | 12.03 | 7 | 21608 | 115812 | 50467697 |
| Synovitis | 28.01 | 12.03 | 9 | 21606 | 123856 | 50459653 |
| Maternal exposure during pregnancy | 27.68 | 12.03 | 17 | 21598 | 159761 | 50423748 |
| Diabetic ketoacidosis | 27.49 | 12.03 | 36 | 21579 | 17836 | 50565673 |
| Bradyarrhythmia | 26.76 | 12.03 | 14 | 21601 | 1876 | 50581633 |
| Acute kidney injury | 26.27 | 12.03 | 177 | 21438 | 227881 | 50355628 |
| Transient ischaemic attack | 25.77 | 12.03 | 48 | 21567 | 32162 | 50551347 |
| Blood urea increased | 25.25 | 12.03 | 40 | 21575 | 23545 | 50559964 |
| Autoimmune myositis | 24.61 | 12.03 | 6 | 21609 | 80 | 50583429 |
| Infusion related reaction | 24.27 | 12.03 | 22 | 21593 | 169535 | 50413974 |
| Ischaemic cardiomyopathy | 24.11 | 12.03 | 14 | 21601 | 2298 | 50581211 |
| Blood glucose abnormal | 23.80 | 12.03 | 21 | 21594 | 6651 | 50576858 |
| Wound | 23.37 | 12.03 | 8 | 21607 | 105786 | 50477723 |
| Cerebrovascular accident | 23.30 | 12.03 | 91 | 21524 | 94589 | 50488920 |
| Lower respiratory tract infection | 23.21 | 12.03 | 6 | 21609 | 95195 | 50488314 |
| Oedema peripheral | 22.82 | 12.03 | 130 | 21485 | 157831 | 50425678 |
| Renal failure | 22.70 | 12.03 | 98 | 21517 | 106535 | 50476974 |
| Treatment noncompliance | 21.74 | 12.03 | 43 | 21572 | 30107 | 50553402 |
| Hypoglycaemic unconsciousness | 21.67 | 12.03 | 9 | 21606 | 713 | 50582796 |
| Carcinoid tumour of the stomach | 20.77 | 12.03 | 6 | 21609 | 158 | 50583351 |
| Metabolic acidosis | 20.70 | 12.03 | 49 | 21566 | 38776 | 50544733 |
| Asthenia | 20.38 | 12.03 | 217 | 21398 | 318825 | 50264684 |
| Arthropathy | 19.75 | 12.03 | 23 | 21592 | 157883 | 50425626 |
| Pancreatitis acute | 19.69 | 12.03 | 36 | 21579 | 23776 | 50559733 |
| Ketoacidosis | 19.65 | 12.03 | 15 | 21600 | 3880 | 50579629 |
| Rhabdomyolysis | 18.41 | 12.03 | 47 | 21568 | 38980 | 50544529 |
| Treatment failure | 18.37 | 12.03 | 19 | 21596 | 137618 | 50445891 |
| Diabetes mellitus | 18.12 | 12.03 | 54 | 21561 | 48979 | 50534530 |
| Hypoglycaemic encephalopathy | 17.66 | 12.03 | 6 | 21609 | 272 | 50583237 |
| Anaphylactic reaction | 17.63 | 12.03 | 57 | 21558 | 53998 | 50529511 |
| Strongyloidiasis | 17.03 | 12.03 | 8 | 21607 | 851 | 50582658 |
| Diabetic retinopathy | 16.96 | 12.03 | 11 | 21604 | 2199 | 50581310 |
| Discomfort | 16.81 | 12.03 | 13 | 21602 | 108367 | 50475142 |
| Mucosal erosion | 16.71 | 12.03 | 9 | 21606 | 1278 | 50582231 |
| Intentional product use issue | 16.67 | 12.03 | 6 | 21609 | 76912 | 50506597 |
| Hepatic steatosis | 16.65 | 12.03 | 34 | 21581 | 24350 | 50559159 |
| Peripheral swelling | 16.49 | 12.03 | 40 | 21575 | 205896 | 50377613 |
| Macular oedema | 16.12 | 12.03 | 13 | 21602 | 3641 | 50579868 |
| Fatigue | 15.98 | 12.03 | 210 | 21405 | 707391 | 49876118 |
| Enterochromaffin cell hyperplasia | 15.97 | 12.03 | 4 | 21611 | 60 | 50583449 |
| Hyperhidrosis | 15.92 | 12.03 | 78 | 21537 | 89348 | 50494161 |
| Necrotising myositis | 15.82 | 12.03 | 6 | 21609 | 374 | 50583135 |
| Hepatic artery thrombosis | 15.79 | 12.03 | 4 | 21611 | 63 | 50583446 |
| Myocardial ischaemia | 15.74 | 12.03 | 22 | 21593 | 11591 | 50571918 |
| Alcoholism | 14.78 | 12.03 | 9 | 21606 | 1611 | 50581898 |
| Lymphocyte count increased | 14.07 | 12.03 | 11 | 21604 | 2948 | 50580561 |
| Hypergastrinaemia | 13.97 | 12.03 | 4 | 21611 | 102 | 50583407 |
| Angina pectoris | 13.90 | 12.03 | 33 | 21582 | 26155 | 50557354 |
| Lip discolouration | 13.84 | 12.03 | 6 | 21609 | 529 | 50582980 |
| Oral mucosal discolouration | 13.60 | 12.03 | 5 | 21610 | 286 | 50583223 |
| Neutropenia | 13.27 | 12.03 | 27 | 21588 | 147938 | 50435571 |
| Blood creatinine increased | 13.25 | 12.03 | 66 | 21549 | 76094 | 50507415 |
| Acute coronary syndrome | 13.06 | 12.03 | 18 | 21597 | 9356 | 50574153 |
| Drug hypersensitivity | 13.03 | 12.03 | 59 | 21556 | 250951 | 50332558 |
| Sinusitis | 12.98 | 12.03 | 34 | 21581 | 170524 | 50412985 |
| Acute myocardial infarction | 12.53 | 12.03 | 34 | 21581 | 29239 | 50554270 |
| Brain death | 12.49 | 12.03 | 10 | 21605 | 2773 | 50580736 |
| Febrile neutropenia | 12.45 | 12.03 | 14 | 21601 | 97653 | 50485856 |
| Drug abuse | 12.41 | 12.03 | 5 | 21610 | 59841 | 50523668 |
| Abdominal discomfort | 12.29 | 12.03 | 54 | 21561 | 231587 | 50351922 |
| Diabetic neuropathy | 12.21 | 12.03 | 11 | 21604 | 3580 | 50579929 |
| Hypersensitivity | 12.13 | 12.03 | 49 | 21566 | 215112 | 50368397 |
| Weight decreased | 12.07 | 12.03 | 146 | 21469 | 221099 | 50362410 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hypoglycaemia | 1091.31 | 11.91 | 607 | 23826 | 47739 | 29502355 |
| Blood glucose increased | 231.75 | 11.91 | 264 | 24169 | 58720 | 29491374 |
| Blood glucose decreased | 178.86 | 11.91 | 116 | 24317 | 11953 | 29538141 |
| Myocardial infarction | 141.18 | 11.91 | 293 | 24140 | 110003 | 29440091 |
| Coronary artery disease | 131.48 | 11.91 | 172 | 24261 | 44018 | 29506076 |
| Cardiac failure congestive | 128.12 | 11.91 | 228 | 24205 | 76353 | 29473741 |
| Lactic acidosis | 95.04 | 11.91 | 121 | 24312 | 30126 | 29519968 |
| Glycosylated haemoglobin increased | 91.59 | 11.91 | 70 | 24363 | 9356 | 29540738 |
| Hyperglycaemia | 77.44 | 11.91 | 117 | 24316 | 34170 | 29515924 |
| Blood mercury abnormal | 70.68 | 11.91 | 19 | 24414 | 188 | 29549906 |
| 5-hydroxyindolacetic acid in urine increased | 68.53 | 11.91 | 19 | 24414 | 213 | 29549881 |
| Off label use | 67.62 | 11.91 | 90 | 24343 | 300710 | 29249384 |
| Counterfeit product administered | 64.29 | 11.91 | 17 | 24416 | 157 | 29549937 |
| Blood pressure systolic increased | 55.45 | 11.91 | 69 | 24364 | 16776 | 29533318 |
| Arteriosclerosis coronary artery | 51.20 | 11.91 | 53 | 24380 | 10552 | 29539542 |
| Cerebrovascular accident | 47.83 | 11.91 | 156 | 24277 | 76755 | 29473339 |
| Drug abuse | 45.68 | 11.91 | 6 | 24427 | 79877 | 29470217 |
| Low density lipoprotein decreased | 44.19 | 11.91 | 20 | 24413 | 1000 | 29549094 |
| Product contamination | 43.08 | 11.91 | 17 | 24416 | 602 | 29549492 |
| Product use in unapproved indication | 40.22 | 11.91 | 11 | 24422 | 86864 | 29463230 |
| Pyrexia | 35.92 | 11.91 | 120 | 24313 | 287502 | 29262592 |
| Hyperoxaluria | 35.22 | 11.91 | 10 | 24423 | 123 | 29549971 |
| Hyperkalaemia | 35.03 | 11.91 | 121 | 24312 | 61271 | 29488823 |
| Myocardial ischaemia | 33.78 | 11.91 | 53 | 24380 | 15975 | 29534119 |
| Mental status changes | 33.61 | 11.91 | 83 | 24350 | 34844 | 29515250 |
| Hepatic neoplasm | 33.11 | 11.91 | 20 | 24413 | 1816 | 29548278 |
| Platelet count normal | 33.01 | 11.91 | 7 | 24426 | 21 | 29550073 |
| Metabolic acidosis | 32.61 | 11.91 | 86 | 24347 | 37576 | 29512518 |
| Expired product administered | 29.80 | 11.91 | 22 | 24411 | 2789 | 29547305 |
| Diabetes mellitus inadequate control | 29.66 | 11.91 | 43 | 24390 | 12091 | 29538003 |
| Blood creatinine increased | 28.94 | 11.91 | 143 | 24290 | 84959 | 29465135 |
| Ischaemic cardiomyopathy | 28.70 | 11.91 | 29 | 24404 | 5609 | 29544485 |
| Hypoglycaemic coma | 27.71 | 11.91 | 19 | 24414 | 2144 | 29547950 |
| Hypoglycaemic encephalopathy | 27.62 | 11.91 | 10 | 24423 | 278 | 29549816 |
| Acute kidney injury | 27.46 | 11.91 | 337 | 24096 | 264930 | 29285164 |
| Haematocrit decreased | 26.90 | 11.91 | 68 | 24365 | 28954 | 29521140 |
| Pancreatitis | 26.09 | 11.91 | 75 | 24358 | 34439 | 29515655 |
| Drug ineffective | 25.85 | 11.91 | 185 | 24248 | 362985 | 29187109 |
| Death | 24.96 | 11.91 | 173 | 24260 | 341911 | 29208183 |
| Congenital absence of bile ducts | 24.40 | 11.91 | 4 | 24429 | 0 | 29550094 |
| Scrotal oedema | 23.98 | 11.91 | 15 | 24418 | 1449 | 29548645 |
| Emotional distress | 23.98 | 11.91 | 42 | 24391 | 13853 | 29536241 |
| Neutropenia | 23.29 | 11.91 | 46 | 24387 | 131665 | 29418429 |
| Oedema peripheral | 22.77 | 11.91 | 155 | 24278 | 103402 | 29446692 |
| Febrile neutropenia | 22.73 | 11.91 | 36 | 24397 | 112204 | 29437890 |
| Neoplasm | 22.28 | 11.91 | 22 | 24411 | 4139 | 29545955 |
| Chest pain | 21.94 | 11.91 | 163 | 24270 | 111810 | 29438284 |
| Quadriparesis | 21.26 | 11.91 | 13 | 24420 | 1206 | 29548888 |
| Otitis externa | 21.25 | 11.91 | 12 | 24421 | 961 | 29549133 |
| Oliguria | 20.70 | 11.91 | 28 | 24405 | 7384 | 29542710 |
| Hyperlipidaemia | 20.37 | 11.91 | 37 | 24396 | 12553 | 29537541 |
| Hirsutism | 19.85 | 11.91 | 7 | 24426 | 180 | 29549914 |
| Injury | 19.10 | 11.91 | 46 | 24387 | 19000 | 29531094 |
| Hepatic pain | 18.69 | 11.91 | 12 | 24421 | 1213 | 29548881 |
| Pancreatitis acute | 18.44 | 11.91 | 53 | 24380 | 24332 | 29525762 |
| Deafness neurosensory | 18.40 | 11.91 | 16 | 24417 | 2562 | 29547532 |
| Nephrocalcinosis | 18.32 | 11.91 | 9 | 24424 | 542 | 29549552 |
| Cardiovascular disorder | 18.07 | 11.91 | 29 | 24404 | 8906 | 29541188 |
| Hospitalisation | 17.55 | 11.91 | 8 | 24425 | 45980 | 29504114 |
| Pneumonia | 17.38 | 11.91 | 175 | 24258 | 319997 | 29230097 |
| Thrombocytopenia | 16.94 | 11.91 | 56 | 24377 | 134767 | 29415327 |
| Blood pH decreased | 16.78 | 11.91 | 14 | 24419 | 2119 | 29547975 |
| Diabetic neuropathy | 16.76 | 11.91 | 18 | 24415 | 3735 | 29546359 |
| Bladder cancer | 16.69 | 11.91 | 30 | 24403 | 10097 | 29539997 |
| Treatment failure | 16.49 | 11.91 | 5 | 24428 | 36934 | 29513160 |
| Cataract | 16.30 | 11.91 | 48 | 24385 | 22330 | 29527764 |
| Paratracheal lymphadenopathy | 16.28 | 11.91 | 5 | 24428 | 82 | 29550012 |
| Middle ear disorder | 16.22 | 11.91 | 3 | 24430 | 3 | 29550091 |
| Poor dental condition | 16.02 | 11.91 | 6 | 24427 | 184 | 29549910 |
| Cutaneous lupus erythematosus | 15.95 | 11.91 | 9 | 24424 | 719 | 29549375 |
| Cardiac disorder | 15.92 | 11.91 | 67 | 24366 | 37196 | 29512898 |
| COVID-19 | 15.85 | 11.91 | 5 | 24428 | 36009 | 29514085 |
| Blood glucose fluctuation | 15.63 | 11.91 | 17 | 24416 | 3580 | 29546514 |
| Body temperature decreased | 15.58 | 11.91 | 30 | 24403 | 10634 | 29539460 |
| Areflexia | 15.57 | 11.91 | 15 | 24418 | 2739 | 29547355 |
| Peripheral vascular disorder | 15.49 | 11.91 | 19 | 24414 | 4548 | 29545546 |
| Lacunar infarction | 15.27 | 11.91 | 15 | 24418 | 2804 | 29547290 |
| Renal injury | 15.27 | 11.91 | 29 | 24404 | 10173 | 29539921 |
| Blood lactic acid increased | 14.92 | 11.91 | 21 | 24412 | 5745 | 29544349 |
| Weight decreased | 14.82 | 11.91 | 190 | 24243 | 150715 | 29399379 |
| Nasal neoplasm | 14.62 | 11.91 | 5 | 24428 | 117 | 29549977 |
| Haemolytic anaemia | 14.38 | 11.91 | 27 | 24406 | 9392 | 29540702 |
| Asthenia | 14.15 | 11.91 | 253 | 24180 | 214997 | 29335097 |
| Hyperlactacidaemia | 14.05 | 11.91 | 14 | 24419 | 2664 | 29547430 |
| Leukopenia | 13.95 | 11.91 | 15 | 24418 | 55188 | 29494906 |
| Dizziness | 13.93 | 11.91 | 227 | 24206 | 189457 | 29360637 |
| Blood glucose | 13.91 | 11.91 | 3 | 24430 | 10 | 29550084 |
| Tympanic membrane disorder | 13.82 | 11.91 | 4 | 24429 | 53 | 29550041 |
| Shock | 13.81 | 11.91 | 44 | 24389 | 21360 | 29528734 |
| C-reactive protein increased | 13.62 | 11.91 | 10 | 24423 | 44253 | 29505841 |
| Hypophagia | 13.55 | 11.91 | 43 | 24390 | 20829 | 29529265 |
| Transient ischaemic attack | 13.37 | 11.91 | 46 | 24387 | 23224 | 29526870 |
| Sensitisation | 13.12 | 11.91 | 5 | 24428 | 161 | 29549933 |
| Product complaint | 12.98 | 11.91 | 19 | 24414 | 5386 | 29544708 |
| Renal failure | 12.79 | 11.91 | 152 | 24281 | 118447 | 29431647 |
| Macrosomia | 12.48 | 11.91 | 4 | 24429 | 76 | 29550018 |
| Blood glucose abnormal | 12.40 | 11.91 | 18 | 24415 | 5065 | 29545029 |
| Drug intolerance | 12.38 | 11.91 | 13 | 24420 | 48366 | 29501728 |
| Condition aggravated | 12.14 | 11.91 | 71 | 24362 | 146224 | 29403870 |
| Crepitations | 11.99 | 11.91 | 13 | 24420 | 2726 | 29547368 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hypoglycaemia | 1611.97 | 10.99 | 865 | 37174 | 89027 | 64371666 |
| Blood glucose increased | 460.35 | 10.99 | 414 | 37625 | 97659 | 64363034 |
| Myocardial infarction | 242.86 | 10.99 | 386 | 37653 | 165435 | 64295258 |
| Lactic acidosis | 228.18 | 10.99 | 228 | 37811 | 61182 | 64399511 |
| Coronary artery disease | 222.01 | 10.99 | 223 | 37816 | 60210 | 64400483 |
| Blood glucose decreased | 218.77 | 10.99 | 148 | 37891 | 22975 | 64437718 |
| Cardiac failure congestive | 212.16 | 10.99 | 319 | 37720 | 130261 | 64330432 |
| Glycosylated haemoglobin increased | 147.87 | 10.99 | 101 | 37938 | 15918 | 64444775 |
| Hyperglycaemia | 122.58 | 10.99 | 165 | 37874 | 60803 | 64399890 |
| Off label use | 116.76 | 10.99 | 121 | 37918 | 632685 | 63828008 |
| Diabetes mellitus inadequate control | 93.93 | 10.99 | 87 | 37952 | 21234 | 64439459 |
| Hyperkalaemia | 77.56 | 10.99 | 179 | 37860 | 100950 | 64359743 |
| Blood mercury abnormal | 77.03 | 10.99 | 19 | 38020 | 188 | 64460505 |
| Counterfeit product administered | 75.84 | 10.99 | 17 | 38022 | 106 | 64460587 |
| 5-hydroxyindolacetic acid in urine increased | 74.72 | 10.99 | 19 | 38020 | 215 | 64460478 |
| Cerebrovascular accident | 71.05 | 10.99 | 210 | 37829 | 137373 | 64323320 |
| Drug ineffective | 69.90 | 10.99 | 258 | 37781 | 839989 | 63620704 |
| Acute kidney injury | 67.24 | 10.99 | 474 | 37565 | 448766 | 64011927 |
| Product use in unapproved indication | 64.22 | 10.99 | 13 | 38026 | 176605 | 64284088 |
| Hypoglycaemic coma | 59.61 | 10.99 | 35 | 38004 | 4239 | 64456454 |
| Drug abuse | 51.91 | 10.99 | 8 | 38031 | 132366 | 64328327 |
| Metabolic acidosis | 51.55 | 10.99 | 123 | 37916 | 70835 | 64389858 |
| Low density lipoprotein decreased | 49.40 | 10.99 | 20 | 38019 | 1070 | 64459623 |
| Arteriosclerosis coronary artery | 47.48 | 10.99 | 52 | 37987 | 15477 | 64445216 |
| Blood creatinine increased | 46 | 10.99 | 180 | 37859 | 135602 | 64325091 |
| Hypoglycaemic encephalopathy | 45.03 | 10.99 | 16 | 38023 | 596 | 64460097 |
| Myocardial ischaemia | 42.30 | 10.99 | 60 | 37979 | 23191 | 64437502 |
| Hepatic neoplasm | 39.79 | 10.99 | 24 | 38015 | 3053 | 64457640 |
| Product contamination | 39.64 | 10.99 | 17 | 38022 | 1052 | 64459641 |
| Renal failure | 39.27 | 10.99 | 211 | 37828 | 181477 | 64279216 |
| Blood pressure systolic increased | 38.39 | 10.99 | 88 | 37951 | 49365 | 64411328 |
| Contraindicated product administered | 37.04 | 10.99 | 9 | 38030 | 107820 | 64352873 |
| Synovitis | 36.62 | 10.99 | 7 | 38032 | 99083 | 64361610 |
| Transient ischaemic attack | 35.84 | 10.99 | 80 | 37959 | 44102 | 64416591 |
| Blood glucose fluctuation | 35.74 | 10.99 | 29 | 38010 | 5926 | 64454767 |
| Pancreatitis | 35.65 | 10.99 | 96 | 37943 | 59511 | 64401182 |
| Platelet count normal | 35.12 | 10.99 | 7 | 38032 | 22 | 64460671 |
| Alopecia | 34.79 | 10.99 | 28 | 38011 | 165662 | 64295031 |
| Pyrexia | 34.59 | 10.99 | 191 | 37848 | 558453 | 63902240 |
| Ischaemic cardiomyopathy | 34.24 | 10.99 | 30 | 38009 | 6808 | 64453885 |
| Mental status changes | 34.09 | 10.99 | 96 | 37943 | 61066 | 64399627 |
| Bladder cancer | 33.99 | 10.99 | 37 | 38002 | 10937 | 64449756 |
| Haematocrit decreased | 31.66 | 10.99 | 87 | 37952 | 54568 | 64406125 |
| Hyperoxaluria | 31.52 | 10.99 | 10 | 38029 | 261 | 64460432 |
| Scrotal oedema | 31.43 | 10.99 | 15 | 38024 | 1192 | 64459501 |
| Oedema peripheral | 31.39 | 10.99 | 222 | 37817 | 210095 | 64250598 |
| Peripheral swelling | 31.08 | 10.99 | 47 | 37992 | 209106 | 64251587 |
| Neutropenia | 30.01 | 10.99 | 60 | 37979 | 239564 | 64221129 |
| Asthenia | 29.74 | 10.99 | 384 | 37655 | 427660 | 64033033 |
| Pancreatitis acute | 29.73 | 10.99 | 73 | 37966 | 42782 | 64417911 |
| Treatment failure | 29.57 | 10.99 | 16 | 38023 | 116800 | 64343893 |
| Drug hypersensitivity | 29.39 | 10.99 | 60 | 37979 | 237755 | 64222938 |
| Blood urea increased | 27.29 | 10.99 | 72 | 37967 | 44081 | 64416612 |
| Diabetic retinopathy | 26.43 | 10.99 | 18 | 38021 | 2821 | 64457872 |
| Infusion related reaction | 26.37 | 10.99 | 35 | 38004 | 164432 | 64296261 |
| Febrile neutropenia | 26.15 | 10.99 | 44 | 37995 | 187613 | 64273080 |
| Hypophagia | 25.96 | 10.99 | 66 | 37973 | 39521 | 64421172 |
| Chest pain | 25.84 | 10.99 | 232 | 37807 | 235748 | 64224945 |
| Oliguria | 25.61 | 10.99 | 37 | 38002 | 14539 | 64446154 |
| Renal injury | 25.43 | 10.99 | 38 | 38001 | 15391 | 64445302 |
| Joint swelling | 25.23 | 10.99 | 56 | 37983 | 215326 | 64245367 |
| Condition aggravated | 24.87 | 10.99 | 124 | 37915 | 372302 | 64088391 |
| Arthropathy | 24.69 | 10.99 | 21 | 38018 | 120946 | 64339747 |
| Headache | 24.23 | 10.99 | 198 | 37841 | 529269 | 63931424 |
| Blood pH decreased | 23.43 | 10.99 | 20 | 38019 | 4382 | 64456311 |
| Torsade de pointes | 23.40 | 10.99 | 39 | 38000 | 17324 | 64443369 |
| Angina unstable | 22.55 | 10.99 | 36 | 38003 | 15431 | 64445262 |
| Hyperhidrosis | 22.34 | 10.99 | 138 | 37901 | 124782 | 64335911 |
| Hypersensitivity | 22.26 | 10.99 | 52 | 37987 | 196400 | 64264293 |
| Pericarditis | 21.89 | 10.99 | 5 | 38034 | 62511 | 64398182 |
| Maternal exposure during pregnancy | 21.67 | 10.99 | 15 | 38024 | 95869 | 64364824 |
| Peripheral vascular disorder | 21.65 | 10.99 | 24 | 38015 | 7237 | 64453456 |
| Angina pectoris | 21.53 | 10.99 | 67 | 37972 | 45014 | 64415679 |
| Shock | 21.28 | 10.99 | 60 | 37979 | 38180 | 64422513 |
| Pemphigus | 20.97 | 10.99 | 5 | 38034 | 60696 | 64399997 |
| Blood glucose abnormal | 20.83 | 10.99 | 26 | 38013 | 8887 | 64451806 |
| Rhabdomyolysis | 20.80 | 10.99 | 108 | 37931 | 91618 | 64369075 |
| Cardiac disorder | 20.53 | 10.99 | 76 | 37963 | 55740 | 64404953 |
| Cardiovascular disorder | 20.51 | 10.99 | 35 | 38004 | 15846 | 64444847 |
| Emotional distress | 20.50 | 10.99 | 57 | 37982 | 35981 | 64424712 |
| Expired product administered | 19.98 | 10.99 | 21 | 38018 | 5966 | 64454727 |
| Bladder transitional cell carcinoma | 19.87 | 10.99 | 14 | 38025 | 2316 | 64458377 |
| Lower respiratory tract infection | 19.83 | 10.99 | 16 | 38023 | 94598 | 64366095 |
| Rash | 19.83 | 10.99 | 174 | 37865 | 458375 | 64002318 |
| Rheumatoid arthritis | 19.82 | 10.99 | 42 | 37997 | 164252 | 64296441 |
| Macular oedema | 19.78 | 10.99 | 19 | 38020 | 4848 | 64455845 |
| Intentional product use issue | 18.92 | 10.99 | 17 | 38022 | 95347 | 64365346 |
| Nephrocalcinosis | 18.80 | 10.99 | 11 | 38028 | 1323 | 64459370 |
| Hepatic pain | 18.80 | 10.99 | 16 | 38023 | 3492 | 64457201 |
| Diabetic ketoacidosis | 18.78 | 10.99 | 49 | 37990 | 29796 | 64430897 |
| Autoimmune myositis | 18.15 | 10.99 | 6 | 38033 | 179 | 64460514 |
| Carcinoid tumour of the stomach | 17.87 | 10.99 | 6 | 38033 | 188 | 64460505 |
| Loss of consciousness | 17.86 | 10.99 | 149 | 37890 | 148216 | 64312477 |
| Glossodynia | 17.67 | 10.99 | 8 | 38031 | 64688 | 64396005 |
| Atrial fibrillation | 17.60 | 10.99 | 166 | 37873 | 170923 | 64289770 |
| Product use issue | 17.31 | 10.99 | 40 | 37999 | 151675 | 64309018 |
| Acute myocardial infarction | 17.15 | 10.99 | 84 | 37955 | 69634 | 64391059 |
| Hyperlipidaemia | 16.86 | 10.99 | 40 | 37999 | 22936 | 64437757 |
| Ventricular hypertrophy | 16.84 | 10.99 | 20 | 38019 | 6496 | 64454197 |
| Hospitalisation | 16.68 | 10.99 | 12 | 38027 | 75195 | 64385498 |
| Gastrointestinal disorder | 16.62 | 10.99 | 17 | 38022 | 89692 | 64371001 |
| Poor dental condition | 16.50 | 10.99 | 7 | 38032 | 422 | 64460271 |
| Weight decreased | 16.43 | 10.99 | 248 | 37791 | 285491 | 64175202 |
| Hirsutism | 16.35 | 10.99 | 9 | 38030 | 964 | 64459729 |
| Blood glucose | 16.27 | 10.99 | 4 | 38035 | 39 | 64460654 |
| Haemodialysis | 16.24 | 10.99 | 33 | 38006 | 17044 | 64443649 |
| Hyperlactacidaemia | 16.18 | 10.99 | 17 | 38022 | 4827 | 64455866 |
| Cardiomegaly | 16.06 | 10.99 | 40 | 37999 | 23644 | 64437049 |
| Lacunar infarction | 16.01 | 10.99 | 18 | 38021 | 5514 | 64455179 |
| Bradyarrhythmia | 15.90 | 10.99 | 15 | 38024 | 3743 | 64456950 |
| Diabetic neuropathy | 15.82 | 10.99 | 18 | 38021 | 5583 | 64455110 |
| Neoplasm | 15.62 | 10.99 | 20 | 38019 | 7011 | 64453682 |
| Therapeutic product effect incomplete | 15.60 | 10.99 | 23 | 38016 | 103459 | 64357234 |
| Diabetes mellitus | 15.58 | 10.99 | 79 | 37960 | 66395 | 64394298 |
| Metabolic alkalosis | 15.34 | 10.99 | 15 | 38024 | 3913 | 64456780 |
| Quadriparesis | 15.25 | 10.99 | 13 | 38026 | 2844 | 64457849 |
| Haemolytic anaemia | 15.24 | 10.99 | 31 | 38008 | 16022 | 64444671 |
| Dehydration | 15.23 | 10.99 | 195 | 37844 | 216568 | 64244125 |
| Paratracheal lymphadenopathy | 15.16 | 10.99 | 5 | 38034 | 148 | 64460545 |
| Hypoglycaemic unconsciousness | 15.16 | 10.99 | 9 | 38030 | 1112 | 64459581 |
| Middle ear disorder | 15.16 | 10.99 | 3 | 38036 | 9 | 64460684 |
| Lymphocyte count decreased | 14.77 | 10.99 | 3 | 38036 | 40696 | 64419997 |
| Fear | 14.67 | 10.99 | 35 | 38004 | 20136 | 64440557 |
| Coronary artery occlusion | 14.61 | 10.99 | 28 | 38011 | 13863 | 64446830 |
| Brain death | 14.38 | 10.99 | 16 | 38023 | 4845 | 64455848 |
| Otitis externa | 14.08 | 10.99 | 11 | 38028 | 2130 | 64458563 |
| Unresponsive to stimuli | 14.07 | 10.99 | 63 | 37976 | 50330 | 64410363 |
| Leukopenia | 13.85 | 10.99 | 24 | 38015 | 101218 | 64359475 |
| Nasal neoplasm | 13.71 | 10.99 | 5 | 38034 | 201 | 64460492 |
| Chronic obstructive pulmonary disease | 13.66 | 10.99 | 80 | 37959 | 70968 | 64389725 |
| Wound | 13.60 | 10.99 | 15 | 38024 | 76462 | 64384231 |
| Helicobacter infection | 13.57 | 10.99 | 3 | 38036 | 38359 | 64422334 |
| Blood lactic acid increased | 13.54 | 10.99 | 23 | 38016 | 10378 | 64450315 |
| Cataract | 13.50 | 10.99 | 63 | 37976 | 51199 | 64409494 |
| Hepatic enzyme increased | 13.46 | 10.99 | 36 | 38003 | 129907 | 64330786 |
| Pemphigoid | 13.44 | 10.99 | 26 | 38013 | 12960 | 64447733 |
| Fatigue | 13.37 | 10.99 | 338 | 37701 | 748392 | 63712301 |
| Syncope | 13.36 | 10.99 | 147 | 37892 | 157488 | 64303205 |
| Enterochromaffin cell hyperplasia | 13.26 | 10.99 | 4 | 38035 | 88 | 64460605 |
| Discomfort | 13.17 | 10.99 | 17 | 38022 | 80861 | 64379832 |
| Dilatation atrial | 13.15 | 10.99 | 13 | 38026 | 3437 | 64457256 |
| Type 2 diabetes mellitus | 13.08 | 10.99 | 47 | 37992 | 33973 | 64426720 |
| Ketoacidosis | 12.91 | 10.99 | 18 | 38021 | 6845 | 64453848 |
| Vitamin B12 deficiency | 12.85 | 10.99 | 16 | 38023 | 5456 | 64455237 |
| Body temperature decreased | 12.81 | 10.99 | 39 | 38000 | 25889 | 64434804 |
| Bundle branch block left | 12.81 | 10.99 | 22 | 38017 | 10012 | 64450681 |
| Renal tubular necrosis | 12.60 | 10.99 | 35 | 38004 | 22075 | 64438618 |
| Myiasis | 12.52 | 10.99 | 3 | 38036 | 26 | 64460667 |
| Death | 12.45 | 10.99 | 205 | 37834 | 482500 | 63978193 |
| Deafness neurosensory | 12.42 | 10.99 | 17 | 38022 | 6357 | 64454336 |
| Insulin C-peptide increased | 12.34 | 10.99 | 4 | 38035 | 112 | 64460581 |
| Areflexia | 12.33 | 10.99 | 15 | 38024 | 4992 | 64455701 |
| Pancreatic carcinoma | 12.28 | 10.99 | 22 | 38017 | 10351 | 64450342 |
| Depressed level of consciousness | 12.15 | 10.99 | 86 | 37953 | 81350 | 64379343 |
| Hepatic steatosis | 12.06 | 10.99 | 43 | 37996 | 30964 | 64429729 |
| Oral mucosal discolouration | 12.05 | 10.99 | 5 | 38034 | 285 | 64460408 |
| Arteriosclerosis | 12.04 | 10.99 | 28 | 38011 | 15849 | 64444844 |
| Electrocardiogram T wave peaked | 12.01 | 10.99 | 7 | 38032 | 836 | 64459857 |
| Leukocytosis | 11.94 | 10.99 | 49 | 37990 | 37691 | 64423002 |
| Drug resistance | 11.91 | 10.99 | 3 | 38036 | 35099 | 64425594 |
| Lung infiltration | 11.84 | 10.99 | 33 | 38006 | 20856 | 64439837 |
| Tricuspid valve incompetence | 11.83 | 10.99 | 29 | 38010 | 16974 | 64443719 |
| Hepatocellular injury | 11.73 | 10.99 | 6 | 38033 | 45229 | 64415464 |
| Intentional overdose | 11.72 | 10.99 | 92 | 37947 | 89852 | 64370841 |
| Renal cyst | 11.61 | 10.99 | 24 | 38015 | 12546 | 64448147 |
| Duodenal ulcer | 11.55 | 10.99 | 26 | 38013 | 14409 | 64446284 |
| Sedation | 11.52 | 10.99 | 5 | 38034 | 41457 | 64419236 |
| Alcoholism | 11.43 | 10.99 | 12 | 38027 | 3405 | 64457288 |
| Injection site erythema | 11.41 | 10.99 | 15 | 38024 | 70785 | 64389908 |
| Halo vision | 11.39 | 10.99 | 6 | 38033 | 589 | 64460104 |
| Mitral valve incompetence | 11.32 | 10.99 | 37 | 38002 | 25501 | 64435192 |
| Anhedonia | 11.31 | 10.99 | 25 | 38014 | 13681 | 64447012 |
| Blood pressure increased | 11.19 | 10.99 | 153 | 37886 | 172399 | 64288294 |
| Treatment noncompliance | 11.13 | 10.99 | 53 | 37986 | 43429 | 64417264 |
| Lip discolouration | 10.99 | 10.99 | 6 | 38033 | 632 | 64460061 |
FDA Adverse Event Reporting System (Pediatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Insulin resistance | 23.88 | 9.17 | 3 | 4 | 3 | 84668 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A10BB01 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Sulfonylureas |
| FDA CS | M0020795 | Sulfonylurea Compounds |
| CHEBI has role | CHEBI:35526 | antidiabetic |
| CHEBI has role | CHEBI:38070 | antiarrhythmic agent |
| CHEBI has role | CHEBI:77194 | ATP:pantothenate 4-phosphotransferase inhibitor |
| CHEBI has role | CHEBI:131770 | CFTR inhibitors |
| MeSH PA | D007004 | Hypoglycemic Agents |
| FDA EPC | N0000175608 | Sulfonylurea |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
| Alcoholism | contraindication | 7200002 | |
| Asthenia | contraindication | 13791008 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Acute vomiting | contraindication | 23971007 | |
| Alcohol intoxication | contraindication | 25702006 | |
| Shock | contraindication | 27942005 | |
| Dehydration | contraindication | 34095006 | |
| Infectious disease | contraindication | 40733004 | |
| Hepatic porphyria | contraindication | 55056006 | DOID:3133 |
| Ketoacidosis | contraindication | 56051008 | |
| Acute nephropathy | contraindication | 58574008 | |
| Metabolic acidosis | contraindication | 59455009 | |
| Hepatic failure | contraindication | 59927004 | |
| Hemolytic anemia | contraindication | 61261009 | DOID:583 |
| Glucose-6-phosphate dehydrogenase deficiency anemia | contraindication | 62403005 | |
| Hypopituitarism | contraindication | 74728003 | DOID:9406 |
| Cardiogenic shock | contraindication | 89138009 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Lactic acidosis | contraindication | 91273001 | DOID:3650 |
| Cobalamin deficiency | contraindication | 190634004 | |
| Decompensated cardiac failure | contraindication | 195111005 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Hypoglycemic disorder | contraindication | 237630007 | |
| Sepsis syndrome | contraindication | 238150007 | |
| Primary adrenocortical insufficiency | contraindication | 373662000 | |
| Adrenal cortical hypofunction | contraindication | 386584007 | DOID:10493 |
| Fever | contraindication | 386661006 | |
| Surgical procedure | contraindication | 387713003 | |
| Severe diarrhea | contraindication | 409587002 | |
| Traumatic injury | contraindication | 417746004 | |
| Fever greater than 100.4 Fahrenheit | contraindication | 426000000 | |
| Radiography with IV Iodinated Contrast Agent | contraindication | ||
| Severe Hypoxemia | contraindication | ||
| Severe Autonomic Insufficiency | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 5.31 | acidic |
| pKa2 | 12.71 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sulfonylurea receptor 1, Kir6.2 | Ion channel | BLOCKER | Kd | 9.52 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Bile salt export pump | Transporter | IC50 | 5.28 | CHEMBL | |||||
| Cytochrome P450 2C9 | Enzyme | INHIBITOR | IC50 | 5.80 | DRUG MATRIX | ||||
| Peroxisome proliferator-activated receptor gamma | Nuclear hormone receptor | Ki | 6.18 | CHEMBL | |||||
| Cystic fibrosis transmembrane conductance regulator | Ion channel | BLOCKER | Ki | 4.66 | IUPHAR | ||||
| Sulfonylurea receptor 2, Kir6.2 | Ion channel | BLOCKER | Ki | 8.21 | WOMBAT-PK | ||||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 4.13 | CHEMBL | |||||
| NACHT, LRR and PYD domains-containing protein 3 | Unclassified | IC50 | 4.92 | CHEMBL | |||||
| CDGSH iron-sulfur domain-containing protein 1 | Unclassified | Ki | 5.78 | CHEMBL | |||||
| ATP-sensitive inward rectifier potassium channel 11 | Ion channel | BLOCKER | IC50 | 5.70 | IUPHAR | ||||
| NACHT, LRR and PYD domains-containing protein 3 | Unclassified | IC50 | 5 | CHEMBL | |||||
| Sur1-Trpm4; Sulfonylurea receptor 1 - Transient receptor potential melastatin 4 | Ion channel | INHIBITOR | EC50 | 7.32 | SCIENTIFIC LITERATURE | ||||
| Bile salt export pump | Transporter | IC50 | 5.55 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018078 | VUID |
| N0000146417 | NUI |
| D00336 | KEGG_DRUG |
| 4018078 | VANDF |
| CHEBI:5441 | CHEBI |
| GBM | PDB_CHEM_ID |
| CHEMBL472 | ChEMBL_ID |
| 2414 | IUPHAR_LIGAND_ID |
| DB01016 | DRUGBANK_ID |
| SX6K58TVWC | UNII |
| 3488 | PUBCHEM_CID |
| 4815 | RXNORM |
| 4790 | MMSL |
| 597 | MMSL |
| d00248 | MMSL |
| 000912 | NDDF |
| 384978002 | SNOMEDCT_US |
| 80870001 | SNOMEDCT_US |
| D005905 | MESH_DESCRIPTOR_UI |
| C0017628 | UMLSCUI |
| 2386 | INN_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Glynase | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0341 | TABLET | 1.50 mg | ORAL | NDA | 26 sections |
| Glynase | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0352 | TABLET | 3 mg | ORAL | NDA | 26 sections |
| Glynase | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-3449 | TABLET | 6 mg | ORAL | NDA | 26 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8034 | TABLET | 1.50 mg | ORAL | ANDA | 24 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8035 | TABLET | 3 mg | ORAL | ANDA | 24 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8036 | TABLET | 6 mg | ORAL | ANDA | 24 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8342 | TABLET | 1.25 mg | ORAL | ANDA | 26 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8343 | TABLET | 2.50 mg | ORAL | ANDA | 26 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8344 | TABLET | 5 mg | ORAL | ANDA | 26 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-9364 | TABLET | 5 mg | ORAL | NDA AUTHORIZED GENERIC | 25 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-9433 | TABLET | 2.50 mg | ORAL | NDA AUTHORIZED GENERIC | 25 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-9477 | TABLET | 1.25 mg | ORAL | NDA AUTHORIZED GENERIC | 25 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1742 | TABLET | 1.25 mg | ORAL | ANDA | 22 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1743 | TABLET | 2.50 mg | ORAL | ANDA | 22 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1744 | TABLET | 5 mg | ORAL | ANDA | 22 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0929 | TABLET | 1.25 mg | ORAL | ANDA | 25 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0930 | TABLET | 2.50 mg | ORAL | ANDA | 25 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0931 | TABLET | 5 mg | ORAL | ANDA | 25 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9918 | TABLET | 1.50 mg | ORAL | ANDA | 20 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9919 | TABLET | 3 mg | ORAL | ANDA | 20 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9920 | TABLET | 6 mg | ORAL | ANDA | 20 sections |
| Glyburide and Metformin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0228-2751 | TABLET, FILM COATED | 1.25 mg | ORAL | ANDA | 27 sections |
| Glyburide and Metformin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0228-2752 | TABLET, FILM COATED | 2.50 mg | ORAL | ANDA | 27 sections |
| Glyburide and Metformin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0228-2753 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 27 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-232 | TABLET | 2.50 mg | ORAL | ANDA | 21 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-300 | TABLET | 5 mg | ORAL | ANDA | 21 sections |
| Glyburide-Metformin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10544-579 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
| Glyburide-Metformin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10544-580 | TABLET | 2.50 mg | ORAL | ANDA | 23 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-467 | TABLET | 2.50 mg | ORAL | ANDA | 22 sections |
| Glyburide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-468 | TABLET | 5 mg | ORAL | ANDA | 22 sections |